The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Tags · Evidence

risk of bias

Structured appraisal of internal validity.

83 topics 21 solved Group: Evidence

Related in this group: STEP programme · SURMOUNT programme · SURPASS programme · SELECT trial · FLOW trial · SOUL trial · TRIUMPH programme · PIONEER programme · SUSTAIN programme · LEADER trial · randomised trial · meta-analysis

83 topics · page 2 of 3

TopicParticipantsRepliesViewsActivity
[2026 update] Confounding by indication, explained with a concrete example
Confounding by indication, explained with a concrete example Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…
DMELCVHNIG+103 116 22k 5mo
Measurement error in a self-reported exposure
Posting this under the heading it deserves: Measurement error in a self-reported exposure Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it before…
LHCKSVCW+117 129 45k 5mo
Heterogeneity as information rather than as a nuisance
Posting this under the heading it deserves: Heterogeneity as information rather than as a nuisance Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it before…
DFRJMNAN+88 95 1.2k 6mo
Journal club: the retatrutide phase 2 obesity paper
Journal club: the retatrutide phase 2 obesity paper — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
LFVDAERASV+7 11 33k 7mo
Selection into a registry and what it does to the estimate
Selection into a registry and what it does to the estimate — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…
SSLMAA 2 55k 7mo
[2026 update] Conference abstracts as evidence: the weakest common citation
Conference abstracts as evidence: the weakest common citation — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-4 ( JAMA , 2024) and finding…
JVVNJB 2 48k 7mo
Tracking a preprint to publication: a worked example
Tracking a preprint to publication: a worked example Writing it up because I had to work it out twice and would rather nobody else did. Session topic: STEP 1 ( N Engl J Med , 2021). Please read it before…
VBUCRSDTSB+133 147 15k 7mo
Pooling trials with different estimands — what changed since
Pooling trials with different estimands — what changed since — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURPASS-4 ( Lancet , 2021) and finding…
BERRMLDYAW+57 64 12k 7mo
What pooling buys you and what it destroys
The question in the title: What pooling buys you and what it destroys I will give what I have already checked below so nobody repeats it. Comparing SURMOUNT-2 ( Lancet , 2023) with LEADER ( N Engl J Med ,…
MDEHDHPMNA+74 83 6.6k 8mo
A preprint whose numbers changed substantially at publication — what changed since
On the subject in the title: A preprint whose numbers changed substantially at publication — what changed since Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it…
BARVKOESSS+3 7 125 8mo
Journal club: how we handle discontinuation in obesity trials — what changed since
Journal club: how we handle discontinuation in obesity trials — what changed since — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it…
OVFVIISLJB+14 18 35k 8mo
Critiquing an observational claim about a class effect — one year on
Critiquing an observational claim about a class effect — one year on — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim…
FELDKRAWDO+5 9 3.2k 8mo
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
AWFLAWCFZL+81 90 54k 9mo
Journal club: indirect comparison between two programmes, defended and attacked — one year on
Posting this under the heading it deserves: Journal club: indirect comparison between two programmes, defended and attacked — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N…
BZNEMETLM+45 50 3k 9mo
Conference abstracts as evidence: the weakest common citation
On the subject in the title: Conference abstracts as evidence: the weakest common citation Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
NSHMTLJDBB+1 5 2k 9mo
Journal club: STEP-HFpEF and symptom endpoints — a second dataset
On the subject in the title: Journal club: STEP-HFpEF and symptom endpoints — a second dataset Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with STEP 4 ( JAMA , 2021) and…
EDCRFKTVIA+11 15 4k 10mo
Reverse causation in a cohort study of weight and outcome — a second dataset
Reverse causation in a cohort study of weight and outcome — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
MRAKANKBVK+112 131 1.5k 10mo
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question
Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it…
DPSGRIEDMB+80 91 10k 11mo
When a preprint is the best available evidence and we say so
When a preprint is the best available evidence and we say so — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…
CPNMKMJE+148 160 31k 11mo
Journal club: STEP-HFpEF and symptom endpoints
Journal club: STEP-HFpEF and symptom endpoints — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and finding…
MREPAKTWJD+18 22 2.5k 11mo
Criticising the method without criticising the authors — one year on
On the subject in the title: Criticising the method without criticising the authors — one year on Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting;…
KOSKJNAKSC+16 20 61k 11mo
Immortal time bias in a claims-database study
Immortal time bias in a claims-database study — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
MACDSOIDNN+29 34 28k 11mo
The "under review" status pill and when a moderator applies it — a second dataset
The "under review" status pill and when a moderator applies it — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021)…
LVARMISLPM+50 54 1.4k 11mo
[2026 update] Journal club: is percentage weight change the right endpoint?
Journal club: is percentage weight change the right endpoint? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021) with…
MLSCNHHRS+105 118 18k 11mo
Journal club: SURMOUNT-1, read without the press release
Journal club: SURMOUNT-1, read without the press release Writing it up because I had to work it out twice and would rather nobody else did. Session topic: STEP 1 ( N Engl J Med , 2021). Please read it before…
LKIRKSASP+139 157 66k 12mo
Random versus fixed effects: choosing rather than defaulting
Random versus fixed effects: choosing rather than defaulting — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before posting;…
NPFSMLAJS+16 20 22k 13mo
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset
Posting this under the heading it deserves: Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with FLOW…
VMLADNWMD+58 64 17k 13mo
Journal club: STEP 4 and what a withdrawal design can prove
On the subject in the title: Journal club: STEP 4 and what a withdrawal design can prove Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
DJTVGHIO+61 65 2k 13mo
Individual participant data versus aggregate data
Posting this under the heading it deserves: Individual participant data versus aggregate data Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it before…
EAKBTEMAK+30 34 64k 14mo
When a preprint is the best available evidence and we say so — a second dataset
When a preprint is the best available evidence and we say so — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med ,…
WMDBSDCAVB+20 24 36k 14mo